The Ginsenoside Rg1 Prevents Transverse Aortic Constriction–Induced Left Ventricular Hypertrophy and Cardiac Dysfunction by Inhibiting Fibrosis and Enhancing Angiogenesis
- 1 July 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 62 (1) , 50-57
Abstract
Background: Ginsenoside Rg1, an important and active ingredient of Panax ginseng, has been shown to exert cardioprotective effects in vivo. The present study aimed to test the hypothesis that ginsenoside Rg1 attenuates cardiac dysfunction in a transverse aortic constriction (TAC)–induced left ventricular hypertrophy in vivo via proangiogenic and antifibrotic effects. Methods: This study investigated the effects of ginsenoside Rg1 in a rat model of TAC-induced left ventricular hypertrophy. Cardiac function was assessed by echocardiography. The antifibrotic and proangiogenic effects were assessed by histopathology and mRNA expression of procollagen I, III, and vascular endothelial growth factor (VEGF) through quantitative real-time PCR. The expression of phosphorylation of Akt, p38 mitogen-activated protein kinase (MAPK), hypoxia inducible factor-1 (HIF-1), and VEGF proteins were examined by Western blotting. Results: Ginsenoside Rg1 treatment significantly decreased TAC-induced myocardial fibrosis and left ventricular hypertrophy, and preserved cardiac function. Ginsenoside Rg1 administration enhanced angiogenesis by increasing the expression of HIF-1 and VEGF. These cardioprotective effects of ginsenoside Rg1 are partially related to the activation of phospho-Akt and inhibition of p38 MAPK. Conclusions: Ginsenoside Rg1 exhibited protective effect against TAC-induced left ventricular hypertrophy and cardiac dysfunction, which is potentially associated with phospho-Akt activation and p38 MAPK inhibition.Keywords
This publication has 31 references indexed in Scilit:
- Bone Morphogenetic Protein-4 Mediates Cardiac Hypertrophy, Apoptosis, and Fibrosis in Experimentally Pathological Cardiac HypertrophyHypertension, 2013
- The Angiogenic Factor Secretoneurin Induces Coronary Angiogenesis in a Model of Myocardial Infarction by Stimulation of Vascular Endothelial Growth Factor Signaling in Endothelial CellsCirculation, 2012
- Stem Cell Antigen 1 Protects Against Cardiac Hypertrophy and Fibrosis After Pressure OverloadHypertension, 2012
- Masked hypertension and echocardiographic left ventricular hypertrophyBlood Pressure Monitoring, 2012
- Repairing chronic myocardial infarction with autologous mesenchymal stem cells engineered tissue in rat promotes angiogenesis and limits ventricular remodelingJournal of Biomedical Science, 2012
- Gastrodin protects against cardiac hypertrophy and fibrosisMolecular and Cellular Biochemistry, 2011
- Association of Left Ventricular Hypertrophy With Incident Hypertension: The Multi-Ethnic Study of AtherosclerosisAmerican Journal of Epidemiology, 2011
- The molecular basis of myocardial hypertrophy and heart failureTrends in Molecular Medicine, 2003
- Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophyEuropean Heart Journal, 2003
- Assessment of preclinical target organ damage in hypertension: left ventricular hypertrophyJournal Of Hypertension, 2002